Abstract
In this article, the authors show the achievements of studies by genetic and pathogenetic methods in the treatment of bronchial asthma (BA) disease to date. However, despite the fact that there are several proposals and methods from researchers in the treatment of AD, the development and standardization of treatment for exacerbation of this disease with systemic glucocorticoids is still relevant. Literary data indicate that until now, the methods of treatment that are based on the sensitivity of lymphocytes toglucocorticosteroids (GCS) in AD have not been sufficiently studied. Therefore, the following studies may allow formingnew approaches to the treatment of bronchial asthma with glucocorticosteroids
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
